Patients with liver cancer can be treated with ablative neutron irradiation if they meet the requirements.
Chang gung memorial hospital studied 102 patients with liver cancer who received proton therapy in Chang gung memorial hospital. Among them, 90 cases had normal liver cirrhosis index (Child-Pugh score A) and 12 cases had impaired liver function (Child-Pugh score B). The results show that when the liver cirrhosis index of patients with liver cancer is normal, that is, their liver function is normal and undamaged, as long as 30% of their normal liver volume is not irradiated by protons, they can be safely treated with extremely high dose of ablative neutron irradiation, and the risk of radiation-induced liver injury is minimal.
For example, an oriental with a normal liver cirrhosis index of 160 cm and 60 kg has a normal liver volume of about1200 c.c. As long as 360c.c.(30%) of the liver is not irradiated, it can be safely treated with protons.
When the liver function of patients with liver cancer is impaired (Child-Pugh score B), 40% of their normal liver volume should not be irradiated by protons, and they can safely receive very high dose of ablative neutron irradiation, with the least risk of liver injury caused by radiation.
The experimental results of Asian patients are also applicable to westerners.
In this study, Chang Gung Memorial Hospital cooperated with Anderson Cancer Center. First of all, patients in Chang Gung Memorial Hospital predicted the safety of proton therapy according to their own liver function, body shape and normal liver volume without radiation exposure, and then converted it into the difference of normal liver volume caused by body shape difference, that is, the same proportion was applied to westerners with larger average liver volume, and patients in Anderson Cancer Center in the United States received proton therapy for liver cancer and got the same conclusion.
Hong Zhihong, deputy chief physician of proton therapy at Chang Gung Memorial Hospital, said that previous studies used the liver volume of patients with liver cancer as a reference for radiotherapy. This breakthrough research achievement of Chang Gung Memorial Hospital has formally established the treatment guidelines for safely screening patients with liver cancer to receive proton therapy, which is a standard applicable to both eastern and western patients. This is an important contribution of this paper to proton therapy of liver cancer.
This research of Chang Gung Memorial Hospital was published in September this year (20 19) in the flagship scientific journal of the American Society of Radiation Oncology, International Journal of Radiation Oncology, Biology and Physics, which was called Red Journal by oncologists, and it is a world-class top journal of radiation oncology.
Top proton centers in Taiwan Province and the United States continue to study proton therapy for liver cancer.
Vice President Hong Zhihong said that this paper was jointly published by Chang Gung Memorial Hospital in Linkou and Anderson Cancer Center in the United States, with Dr. Xie Chengen from the Department of Radiation Oncology of Chang Gung Memorial Hospital as the first author, and Vice President Hong Zhihong and Dr. Krishnan)*** from Anderson Cancer Center as the co-directors. Dr. Xie Chengen is now studying for a doctorate at Anderson Cancer Center, funded by Chang Gung Memorial Hospital. Through this paper, the international cooperation between the top proton centers in Taiwan Province and the United States was promoted, and the two sides continued to do further research cooperation in proton therapy for liver cancer. Update results are expected soon.
The proton center of Chang Gung Memorial Hospital in Linkou began to treat patients from 20 15 1 1. Vice President Hong Zhihong pointed out that more than 2,200 patients have received proton therapy so far, of which 24% are patients with liver-related tumors. The 3-year control rate and survival rate of liver cancer patients who received radical treatment were 90% and 50%, respectively, which were consistent with the results reported by foreign proton centers. The average tumor size of patients receiving proton therapy in Taiwan Province Province is about 7 cm (2/3 is more than 5 cm, 1/3 is more than 10 cm), while the average tumor size abroad is mostly less than 5 cm. This shows that the level of proton therapy in Taiwan Province Province has reached the international level. Although the three-year follow-up period is still insufficient in the survival rate of patients, the evaluation of treatment safety is enough, so Chang Geng's analysis and publication of his treatment experience has attracted the attention of the world academic community.
Vice President Hong Zhihong said that in the same issue of the journal, it is also valued. The report on the long-term effect of proton therapy for liver cancer published by Massachusetts General Hospital shows that proton therapy greatly reduces the irradiation to normal liver tissues and reduces the side effects of liver function damage caused by irradiation, thus improving the overall treatment survival rate: the average survival rate of patients receiving X-ray therapy is 14 months, while the average survival rate of patients receiving proton therapy is 3 1 month; The two-year survival rate was 28.6% by X-ray and 59. 1% by proton.
Vice President Hong Zhihong believes that this result is consistent with that observed by proton therapy for Chang Gung's liver cancer. Both papers show that proton therapy is far safer than X-ray therapy, so that patients can get better therapeutic effect.
Topic: Linkou, Chang Gung, Anderson Cancer Center, USA, liver cancer, proton therapy for Chang Gung liver cancer.